We are international
Donate
• treatment options TEXT SIZE   
novel therapies    back

FDA Approves Subcutaneous Administration of VELCADE® In All Approved Indications
Study met primary efficacy endpoint of non-inferiority between subcutaneous and intravenous administration.
Study results also indicated overall similar safety profile with differences in incidence of peripheral neuropathy.
01.23.12

1 Comment

I started receiving subcutaneous administration of VELCADE four weeks ago and overall I have felt ok since then. Side effects have been minimum and I tolerate it with no major problems so far. The only battle I have been in is constipation. Subcutaneous VELCADE is working well for me!

Leave a comment

 related articles
ASH 2011: Dr. Moreau - Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics
Dr. Moreau - A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Dr. Noopur Raje Discusses Her Research Interests in MM, Including Subcutaneous VELCADE


You might also be interested in:

ASH 2011: Dr. Moreau - Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics
Philippe Moreau, MD
University Hospital
Nantes, France

Dr. Moreau - A Phase 3 Prospective Randomized International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib In Patients with Relapsed Multiple Myeloma
Philippe Moreau, MD
University Hospital
Nantes, France

Dr. Noopur Raje Discusses Her Research Interests in MM, Including Subcutaneous VELCADE